Combination of a PD-1 antagonist and eribulin for treating cancer
US10945990B2 · kind B2 · utility
6Cited by
10References
6Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 3, 2016 |
| Grant date | Mar 16, 2021 |
| Priority date | — |
| Expiry date | Jun 27, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2300/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and eribulin or a pharmaceutically acceptable salt thereof, and the use of the combination therapies for the treatment of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.